<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>488-SULFAFURAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SULFAFURAZOLE" rxcui="10207">
<ATC code="J01EB05" />
<ATC code="S01AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the vitamin K antagonist and of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Precaution of use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the antibiotic and a week after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>488-SULFAFURAZOLE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="SULFAFURAZOLE" rxcui="10207">
<ATC code="J01EB05" />
<ATC code="S01AB02" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of phenytoin up to toxic values (inhibition of its metabolism)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>The use of another class of antibiotic is preferred; if not, strict clinical monitoring, concentration dosage of phenytoin, and possible adjustment of its dosage during the treatment with the sulfonamide antibiotic and after it is stopped.</COMMENT>
</INTERACTION>
</INTERACTIONS>
